{"id":"meropenem-2-grams-tid","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Diarrhea"},{"rate":"3-8","effect":"Nausea"},{"rate":"2-5","effect":"Headache"},{"rate":"2-4","effect":"Phlebitis at injection site"},{"rate":"0.5-1","effect":"Seizures"},{"rate":"1-3","effect":"Hypersensitivity reactions"}]},"_chembl":{"chemblId":"CHEMBL127","moleculeType":"Small molecule","molecularWeight":"383.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and causing cell wall degradation. This leads to bacterial cell lysis and death. It has activity against a wide range of gram-positive, gram-negative, and anaerobic bacteria.","oneSentence":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:53.150Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3)"}]},"trialDetails":[{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT03671967","phase":"PHASE4","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2019-05-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":1084},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT05578586","phase":"NA","title":"A Pilot Study for Optimizing Meropenem Administration in the ICU","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2021-12-14","conditions":"Drug Effect","enrollment":50},{"nctId":"NCT03174184","phase":"PHASE2","title":"Early Bactericidal Activity of Rifampin + Meropenem + Amoxicillin/Clavulanate in Adults With Pulmonary TB","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-08-23","conditions":"Tuberculosis, Pulmonary","enrollment":112},{"nctId":"NCT04238390","phase":"PHASE3","title":"Ceftolozane-tazobactam Versus Meropenem for ESBL and AmpC-producing Enterobacterales Bloodstream Infection","status":"WITHDRAWN","sponsor":"The University of Queensland","startDate":"2022-01","conditions":"Bacteremia Caused by Gram-Negative Bacteria","enrollment":""},{"nctId":"NCT03622450","phase":"PHASE2, PHASE3","title":"The Effect of Colistin Inhalation on Ventilator Associated Pneumonia","status":"COMPLETED","sponsor":"Nourhan Hassan Osama Thuraya Mohamed","startDate":"2016-01-02","conditions":"Ventilator Associated Pneumonia","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Merrem"],"phase":"phase_3","status":"active","brandName":"MEROPENEM 2 grams TID","genericName":"MEROPENEM 2 grams TID","companyName":"BioVersys SAS","companyId":"bioversys-sas","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections (specific indication under investigation by BioVersys SAS in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}